Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience

Lung Cancer

Volumn 52, Issue 1, 2006, Pages 75-81

  Kim, Jee Hyun ^a,l   Kim, Si Young ^b   Jung, Kyung Hae ^c,m   Park, Keunchil ^d   Suh, Cheol Won ^e   Lim, Ho Young ^f   Kim, Yeul Hong ^g   Ryoo, Baek Yeol ^h   Cho, Eun Kyung ⁱ   Park, Byung Joo ^j   Heo, Dae Seog ^a,k  

^a Seoul National University Hospital   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Asan Medical Center   (South Korea)

^f Ajou University Medical Center   (South Korea)

^g Korea University Ansan Hospital   (South Korea)

^h Korea Cancer Center Hospital   (South Korea)

ⁱ Gachon University College of Medicine   (South Korea)

^j Seoul National University   (South Korea)

^k Seoul National University College of Medicine   (South Korea)

^l Seoul National University Bundang Hospital   (South Korea)

^m National Cancer Center   (South Korea)

more..

Author keywords

Cisplatin; Clinical trials; Etoposide; Gemcitabine; Non small cell lung cancer; Phase II

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; FEMALE; GRANULOCYTOPENIA; HUMAN; KOREA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33644767878     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.11.015     Document Type: Article

References (23)

1. R. Peto, Z.M. Chen, and J. Boreham Tobacco - the growing epidemic Nat Med 5 1999 15 17
2. Headquarter of Korea Central Cancer Registry. 2002 annual report of the Korea Central Cancer Registry, http://www.ncc.re.kr.
3. D.S. Schrump, N.K. Altorki, C.L. Henschke, D. Carter, A.T. Turrisi, and M.E. Gutierrez Cancer of the lung V.T.J. DeVita S. Hellman S.A. Rosenberg Cancer: principles and practice of oncology 7th ed. 2005 J.B. Lippincott Co. Philadelphia 753 810
4. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
5. M.H. Cullen, L.J. Billingham, C.M. Woodroffe, A.D. Chetiyawardana, N.H. Gower, and R. Joshi Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life J Clin Oncol 17 1999 3188 3194
6. S. Thongprasert, P. Sanguanmitra, W. Juthapan, and J. Clinch Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy Lung Cancer 24 1999 17 24
7. M. Helsing, B. Bergman, L. Thaning, and U. Hero Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicentre randomised phase III trial. Joint Lung Cancer Study Group Eur J Cancer 34 1998 1036 1044
8. S.G. Spiro, R.M. Rudd, R.L. Souhami, J. Brown, D.J. Fairlamb, and N.H. Gower Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life Thorax 59 2004 828 836
9. D.G. Pfister, D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, and S. Baker Jr. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
10. F. Cardenal, M.P. Lopez-Cabrerizo, A. Anton, V. Alberola, B. Massuti, and A. Carrato Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 17 1999 12 18
11. P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, and E. Rowinsky Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J Clin Oncol 18 2000 623 631
12. G. Giaccone, T.A. Splinter, C. Debruyne, G.S. Kho, P. Lianes, and N. van Zandwijk Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group J Clin Oncol 16 1998 2133 2141
13. K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, and N. Katakami Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group J Clin Oncol 22 2004 254 261
14. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
15. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandier, and J. Krook Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
16. T. Le Chevalier, G. Scagliotti, R. Natale, S. Danson, R. Rosell, and R. Stahel Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes Lung Cancer 47 2005 69 80
17. M.J. Millward, M.J. Boyer, M. Lehnert, S. Clarke, D. Rischin, and B.-C. Goh Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients Ann Oncol 14 2003 449 454
18. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J Clin Oncol 21 2003 2237 2246
19. Y. Ohe, and N. Saijo Results of recent Japanese clinical trials in lung cancer Clin Lung Cancer 3 2002 243 248
20. C.M. Tammemagi, C. Neslund-Dudas, M. Simoff, and P. Kvale In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival J Clin Epidemiol 57 2004 597 609
21. V.H. Murthy, H.M. Krumholz, and C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
22. H. Kusaba, T. Tamura, T. Shimoyama, K. Hotta, A. Inoue, and H. Nokihara Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer Jpn J Clin Oncol 32 2002 43 47
23. H. Kunikane, Y. Kurita, K. Watanabe, A. Yokoyama, K. Noda, and Y. Fujita A study of the combination of gemcitabine hydrochloride (LY 188011) and cisplatin in non-small-cell lung cancer: 3-week schedule Int J Clin Oncol 6 2001 284 290